Singapore markets open in 2 hours 52 minutes

Molecular Templates, Inc. (MTEM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.0800+0.0700 (+1.75%)
At close: 04:00PM EST
4.0800 0.00 (0.00%)
After hours: 04:00PM EST

Molecular Templates, Inc.

9301 Amberglen Boulevard
Suite 100
Austin, TX 78729
United States
512 869 1555
http://www.mtem.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees262

Key executives

NameTitlePayExercisedYear born
Dr. Eric E. PomaCEO, Chief Scientific Officer & Director820.9kN/A1972
Ms. Jason S KimPres & COO590.25kN/A1975
Dr. Roger J. WaltzmanChief Medical Officer572.91kN/A1968
Mr. Sean McLennanSr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & TreasurerN/AN/A1970
Mr. Kurt ElsterExec. VP of Corp. Devel.N/AN/A1967
Dr. Jack Higgins Ph.D.Exec. VP of Operations & Head of ManufacturingN/AN/A1980
Dr. Erin Willert Ph.D.Exec. VP of R&DN/AN/A1982
Dr. Jen-Sing Liu Ph.D.Exec. VP of ManufacturingN/AN/A1963
Dr. Nenad Sarapa M.D., M.S.Sr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas.

Corporate governance

Molecular Templates, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.